Canaccord raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $587 from $526 and keeps a Buy rating on the shares. The firm updated its model to reflec the impending launch of Rezdiffra in the EU as well as coming out of 3Q earnings.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal price target raised to $568 from $500 at H.C. Wainwright
- Madrigal Pharmaceuticals presents new data on Rezdiffra
- Madrigal’s Earnings Call: Rezdiffra’s Success and Future Outlook
- Madrigal Pharmaceuticals price target raised to $527 from $485 at Citizens JMP
- Madrigal Pharmaceuticals Reports Strong Q3 2025 Growth